



SDI Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_50471
Title of the Manuscript:	METHOD DEVELOPMENT FOR 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide BY REVERSE PHASE HPLC: NEW ANALYTICAL TECHNIQUE
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<ol style="list-style-type: none"> 1. The manuscript represented a novel analytical approach with data within the pharmacopeia limits. A MINOR REVISION is recommended. 2. When there is a possibility to write the common name MELOXICAM, that the whole world is well acquainted, then avoid writing the IUPAC name. 3. Subscript the molecular formula. 4. Mention the methods for Linearity, LOD, LOQ, etc. in the manuscript. Refer relevant papers for the complete content. 5. et al. Must be italicized. 	The manuscript has been modified accordingly
Minor REVISION comments		
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	